Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, November 26, 2014
Technology Networks
Register | Sign in
Home Page>News

  News Archive

Promethera Receives Approval to Enroll Patients in the Imminent HEP002 Phase IIb/III Clinical Trial
Thursday, October 16, 2014
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients.

PCI Announces Opening of North American Clinical Facility
Thursday, October 16, 2014
PCI opens North American storage and distribution facility for investigational medicinal products.

Endo to Acquire Auxilium Pharmaceuticals in a Cash and Stock Transaction
Thursday, October 16, 2014
Combination designed to create leading specialty healthcare company with expanded platform for future growth.

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration
Thursday, October 16, 2014
Collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma.

CSL Behring Launches $450 Million Capacity Expansion
Thursday, October 16, 2014
Company further increases global manufacturing capabilities with production expansions of albumin in Australia and plasma intermediates in U.S. to meet escalating patient demand for innovative treatments.

INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents
Thursday, October 16, 2014
Audit to encompass regulatory documents for PH-10 and PV-10.

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Thursday, October 16, 2014
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).

Debiopharm Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450
Wednesday, October 15, 2014
Debio 1450 - A highly potent anti-infective agent selectively active against Staphylococcus species.

Dilafor Signs Supply and Partnership Agreement with Opocrin
Wednesday, October 15, 2014
Opocrin appointed as the main commercial manufacturing partner for Dilafor's candidate drug tafoxiparin.

<< 5 6 7 8 9 10 11 >>
Showing Results 71 - 80 of 3275
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to